Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of asthma
3.2.1.2 Technological advancements
3.2.1.3 Rising expenditure on the R&D of novel biologics
3.2.1.4 Increase in awareness regarding asthma management
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Loss of patent protection for popular drugs
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Reimburesemnt scenario
3.7 Regulatory landscape
3.8 Technological landscape
3.9 Future market trends
3.10 GAP analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Combination therapies (ICS/LABAs)
5.3 Long-acting beta agonists (LABAs)
5.4 Short-acting beta agonists (SABAs)
5.5 Inhaled corticosteroids (ICS)
5.6 Oral and intravenous corticosteroids
5.7 Leukotriene modifiers
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Long-term asthma control medications
6.3 Quick-relief (rescue) medications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Inhaled
7.3 Oral
7.4 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Brick & mortar
8.3 Hospital pharmacies
8.4 E-commerce
Chapter 9 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Ambulatory surgical centers
9.4 Homecare settings
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AstraZeneca
11.2 Boehringer Ingelheim
11.3 Cipla Ltd.
11.4 Covis Pharma
11.5 GSK plc
11.6 Merck & Co., Inc.
11.7 Novartis Pharmaceuticals Corporation
11.8 Regeneron Pharmaceuticals, Inc.
11.9 Sanofi
11.10 Teva Pharmaceutical Industries Ltd.
